Inotiv, Inc. (NOTV)
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries. The company also sells analytical instruments to the pharmaceutical development and contract research industries.
Company Overview
Inotiv, Inc. (NOTV) offers comprehensive drug discovery and development services, coupled with specialized analytical instruments, positioning it as a key partner for pharmaceutical, chemical, and medical device companies seeking to navigate complex regulatory landscapes and accelerate research timelines.
Investment Thesis
Inotiv presents a compelling investment opportunity due to its comprehensive service offerings in the drug discovery and development space. The company's two-pronged approach, encompassing both contract research services and research product sales, diversifies its revenue streams and mitigates risk. With a market capitalization of $0.01 billion, Inotiv is positioned for growth as the pharmaceutical and biotechnology industries continue to expand. Key value drivers include the increasing demand for preclinical research services and the adoption of Inotiv's innovative in vivo sampling technologies. The company's agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program highlights its capabilities and potential for future partnerships. Investors should monitor Inotiv's ability to improve its profit margin, which currently stands at -13.4%, and capitalize on growth opportunities within the expanding drug development market.
Key Highlights
- Market Cap of $0.01 billion indicates a small-cap company with potential for growth.
- P/E ratio of -0.21 reflects current losses but also potential for future earnings growth.
- Gross Margin of 20.9% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Beta of 4.16 suggests high volatility compared to the market, indicating higher risk and potential reward.
- The company operates through two segments, Contract Research Services and Research Products, diversifying its revenue streams.
Competitors
Strengths
- Comprehensive service offerings in drug discovery and development.
- Proprietary in vivo sampling systems and analytical instruments.
- Established reputation and long-standing industry presence.
- Experienced management team with deep expertise in the pharmaceutical industry.
Weaknesses
- Negative profit margin (-13.4%) indicates financial challenges.
- High beta (4.16) suggests significant stock price volatility.
- Small market capitalization limits access to capital.
- Dependence on the pharmaceutical industry, which is subject to regulatory changes and economic cycles.
Catalysts
- Upcoming: Potential new partnerships with pharmaceutical companies to conduct preclinical toxicity studies.
- Ongoing: Increasing demand for contract research services due to the growing pharmaceutical and biotechnology industries.
- Ongoing: Adoption of Inotiv's in vivo sampling systems by research institutions and pharmaceutical companies.
- Ongoing: Expansion of service offerings to include new areas of drug discovery and development.
Risks
- Potential: Negative profit margin may deter investors and limit financial flexibility.
- Potential: High beta indicates significant stock price volatility, which could lead to losses for investors.
- Ongoing: Intense competition from other CROs and analytical instrument providers.
- Potential: Regulatory changes could impact the drug development process and reduce demand for Inotiv's services.
Growth Opportunities
- Expansion of Contract Research Services: The global contract research organization (CRO) market is projected to reach $79.2 billion by 2027. Inotiv can capitalize on this growth by expanding its service offerings and geographic reach within its Contract Research Services segment. This includes investing in advanced technologies and expertise to meet the evolving needs of pharmaceutical and biotechnology companies. Timeline: Ongoing.
- Increased Adoption of In Vivo Sampling Systems: The market for in vivo sampling systems is growing due to the increasing demand for real-time monitoring of drug effects in preclinical studies. Inotiv can drive adoption of its Culex family of automated in vivo sampling and dosing instruments by highlighting their benefits in terms of data quality, efficiency, and cost savings. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Inotiv can pursue strategic partnerships and acquisitions to expand its capabilities and market presence. This includes partnering with complementary service providers or acquiring companies with specialized expertise in areas such as toxicology, pathology, or bioanalysis. Timeline: Ongoing.
- Geographic Expansion: Inotiv operates in the United States, rest of North America, the Pacific Rim, and Europe. Expanding into new geographic markets, particularly in Asia-Pacific, can provide significant growth opportunities. This includes establishing local offices, building relationships with key customers, and adapting its service offerings to meet the specific needs of each market. Timeline: Ongoing.
- Development of New Analytical Instruments: Inotiv can invest in the development of new analytical instruments to address emerging needs in the pharmaceutical and biotechnology industries. This includes developing instruments for advanced applications such as proteomics, metabolomics, and genomics. Timeline: Ongoing.
Opportunities
- Expansion of contract research services to capitalize on the growing CRO market.
- Increased adoption of in vivo sampling systems in preclinical studies.
- Strategic partnerships and acquisitions to expand capabilities and market presence.
- Geographic expansion into new markets, particularly in Asia-Pacific.
Threats
- Intense competition from other CROs and analytical instrument providers.
- Regulatory changes that could impact the drug development process.
- Economic downturns that could reduce demand for research services.
- Technological advancements that could render existing products and services obsolete.
Competitive Advantages
- Specialized Expertise: Inotiv possesses deep expertise in drug discovery and development, providing a competitive advantage in the market.
- Comprehensive Service Offering: The company offers a broad range of services, from early-stage screening to late-stage clinical trials, making it a one-stop shop for its customers.
- Proprietary Technology: Inotiv's in vivo sampling systems and analytical instruments provide a technological edge over competitors.
- Established Reputation: With a history spanning several decades, Inotiv has built a strong reputation for quality and reliability.
About
Founded in 1974 and headquartered in West Lafayette, Indiana, Inotiv, Inc., formerly known as Bioanalytical Systems, Inc., has evolved into a comprehensive provider of drug discovery and development solutions. The company operates through two primary segments: Contract Research Services and Research Products. The Contract Research Services segment delivers a suite of services, including screening, pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing. These services support pharmaceutical, chemical, and medical device companies in navigating the complex regulatory landscape and accelerating their research timelines. The Research Products segment focuses on the design, development, manufacturing, and marketing of in vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography and electrochemistry instruments platforms, and analytical products. Inotiv serves a global clientele, operating in the United States, rest of North America, the Pacific Rim, and Europe. Inotiv's agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program exemplifies its role in advancing innovative healthcare solutions. With a history spanning several decades, Inotiv has established itself as a trusted partner in the drug development ecosystem.
What They Do
- Provides screening and pharmacological testing services.
- Offers nonclinical safety testing services.
- Provides formulation development services.
- Ensures regulatory compliance for pharmaceutical products.
- Conducts quality control testing services.
- Develops and validates analytical methods.
- Offers drug metabolism, bioanalysis, and pharmacokinetics testing.
- Manufactures and markets in vivo sampling systems.
Business Model
- Generates revenue through contract research services provided to pharmaceutical, chemical, and medical device industries.
- Sells analytical instruments and related accessories to research and development organizations.
- Offers specialized testing services, including drug metabolism and bioanalysis.
- Provides climate-controlled archiving services for customer data and samples.
Industry Context
Inotiv operates within the medical diagnostics and research industry, a sector experiencing steady growth driven by increasing healthcare expenditures and advancements in pharmaceutical research. The competitive landscape includes companies like BDSX, BEAT, BIAF, CELU, and FGEN, each vying for market share in specific niches. The demand for contract research services is rising as pharmaceutical companies seek to outsource preclinical and clinical trials to reduce costs and accelerate drug development timelines. Inotiv's focus on providing comprehensive solutions, including both research services and analytical instruments, positions it to capitalize on these trends and gain a competitive edge.
Key Customers
- Pharmaceutical companies
- Chemical companies
- Medical device companies
- Contract research organizations
- Academic research institutions
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $121M | -$28M | $0.00 |
| Q3 2025 | $138M | -$9M | $0.00 |
| Q2 2025 | $131M | -$18M | $0.00 |
| Q1 2025 | $124M | -$15M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Inotiv, Inc. (NOTV) stock price: $0.58 (+0.04, +7.73%)
Why Bull
- •Insider buying has increased recently, indicating confidence from leadership in the company's future.
- •Community sentiment has turned positive, with discussions highlighting Inotiv's strong pipeline of services and innovations.
- •Analysts are optimistic about Inotiv's potential due to recent contract wins and partnerships that enhance its market position.
- •The overall market perception has shifted favorably with growing interest in biotech and life sciences, benefiting Inotiv.
Why Bear
- •Recent community discussions reflect concerns about regulatory challenges that could impact Inotiv's operations.
- •Some investors are wary of the company's past performance and ongoing volatility in the biotech sector.
- •There are fears regarding competition in the market, with new entrants potentially threatening Inotiv's market share.
- •Market sentiment remains cautious, with some analysts highlighting the need for more consistent growth to regain investor trust.
Latest News
-
Earnings Scheduled For February 9, 2026
benzinga · Feb 9, 2026
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga · Nov 19, 2025
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Nov 18, 2025
-
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November
benzinga · Nov 18, 2025
Technical Analysis
Rationale
AI-generated technical analysis for NOTV including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Inotiv, Inc. (NOTV) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for NOTV.
Make a Prediction
Set your price target for Inotiv, Inc. (NOTV), choose a timeframe, and track your prediction accuracy.
Current price: $0.58
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NOTV.
Price Targets
Wall Street price target analysis for NOTV.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 4.5% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 6/100
Gross margin of 23.5% is acceptable but leaves limited room for R&D and marketing investment.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 3/100
Net insider selling of -$0.06M may indicate reduced confidence or routine diversification by executives.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates NOTV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Earnings Scheduled For February 9, 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November
Frequently Asked Questions
What does Inotiv, Inc. do?
Inotiv, Inc. is a contract research organization (CRO) and provider of research products that supports the drug discovery and development efforts of pharmaceutical, chemical, and medical device companies. The company operates through two segments: Contract Research Services, which offers a range of preclinical testing and regulatory compliance services, and Research Products, which designs, develops, and markets in vivo sampling systems and analytical instruments. Inotiv's comprehensive solutions help its customers accelerate research timelines, reduce costs, and navigate the complex regulatory landscape.
Is NOTV stock a good buy?
NOTV stock presents a mixed investment profile. While the company operates in a growing industry and offers comprehensive services, its negative profit margin and high beta raise concerns. Investors should consider the potential for future earnings growth and the company's ability to capitalize on growth opportunities. A thorough analysis of Inotiv's financial performance, competitive positioning, and growth strategy is essential before making an investment decision. The small market cap also indicates higher risk.
What are the main risks for NOTV?
The main risks for Inotiv include its negative profit margin, which indicates financial instability, and its high beta, which suggests significant stock price volatility. Intense competition from other CROs and analytical instrument providers poses a threat to the company's market share. Regulatory changes in the pharmaceutical industry could also impact demand for Inotiv's services. Additionally, economic downturns could reduce research spending and negatively affect the company's revenue.
Is NOTV a good stock to buy?
Whether NOTV is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the NOTV MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is NOTV data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for NOTV?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Inotiv, Inc..
Who are NOTV's main competitors?
Inotiv, Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how NOTV compares.
What do analysts say about NOTV?
Analyst ratings and price targets for NOTV are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is NOTV's market cap?
Market capitalization reflects the total market value of NOTV's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has NOTV stock performed recently?
Check the Chart & Info tab for NOTV's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in NOTV?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for NOTV-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling NOTV?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for NOTV.
Is NOTV a good stock for beginners?
Inotiv, Inc. (NOTV) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is NOTV for first-time investors?
Every stock carries risk, including Inotiv, Inc. (NOTV). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like NOTV.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data as of 2026-02-09.
- Financial metrics are subject to change.
- Investment decisions should be made based on individual risk tolerance and financial goals.